Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
Neeraj Agarwal, James Brugarolas, Pooja Ghatalia, S. George, John B.A.G. Haanen, Howard Gurney, Rahul Ravilla, Astrid van der Veldt, Benoit Beuselinck, И. А. Покатаев, Britt B.M. Suelmann, Mark Tuthill, Daniel A. Vaena, Flora Zagouri, Jane Wu, R.F. Perini, Y. Liu, Jamie Merchan, M.B. Atkins
Topics & Concepts
MedicineRenal cell carcinomaRegimenClinical endpointInternal medicineClear cell renal cell carcinomaAdverse effectTyrosine-kinase inhibitorPhases of clinical researchGastroenterologyTolerabilityUrologyToxicityRandomized controlled trialCancerCancer, Hypoxia, and MetabolismRenal cell carcinoma treatmentCancer Research and Treatments